Opendata, web and dolomites

Simecos SIGNED

A New Adjuvant Nutraceutical from the North Atlantic Ocean for Breast, Lung and Pancreatic Cancer Patients

Total Cost €


EC-Contrib. €






 Simecos project word cloud

Explore the words cloud of the Simecos project. It provides you a very rough idea of what is the project "Simecos" about.

treatment    optimise    validate    2020    extracted    rates    business    purified    ph2    siglufj    chitinase    discovered    fishery    effectiveness    exoskeleton    inflammatory    patients    ykl    inhibition    compounds    human    quality    45m    cancer    biological    marine    adjuvant    worsen    hence    chos    validated    decrease    inflammation       vivo    proven    biotechnology    budget    2002    diagnosed    therapeutic    fatigue    trial    simecos    return    2008    trade    chemotherapy    roi    village    manufacturing    market    atlantic    rdur    considering    chitooligosaccharides    effect    20    molecules    anti    genis    started    prove    feasibility    clinical    thanks    enzyme    clinically    82    diseases    health    lung    north    vitro    30       solutions    ouml    fishing    crisis    95    levels    18m    life    supplements    give    iceland    780    shrimp    nutraceutical    2024    forefront    respectively    investment    tumour    opportunity    chitin    ph1    survival    complementary    confirmed    pay    expansion    profit    entail    breast    pain    pancreatic    industry   

Project "Simecos" data sheet

The following table provides information about the project.


Organization address
address: ADALGOTU 34
postcode: 580
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Project website
 Total cost 2˙180˙387 €
 EC max contribution 1˙526˙271 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2020-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENIS HF IS (SIGLUFJORDUR) coordinator 1˙526˙271.00


 Project objective

Genis is based in Siglufjördur, a village in the North Iceland traditionally focused on the fishing industry. After the fishery crisis worsen in 2008, Siglufjördur started to pay attention to the marine biotechnology, with Genis at the forefront. Hence, since 2002, we develop health products based in T-ChOS™ (Therapeutic Chitooligosaccharides), which are compounds obtained from chitin extracted from the North Atlantic shrimp exoskeleton. T-ChOS™ show a strong anti-inflammatory effect based in a novel biological pathway discovered by Genis: Inhibition of the YKL-40 chitinase enzyme, whose levels are very high in several diseases as cancer. Our in vitro, in vivo and human studies prove that T-ChOS™ can decrease inflammation and enhance tumour response to chemotherapy. During the Ph1 project, we confirmed the feasibility of developing a nutraceutical based on T-ChOS™ to use as an adjuvant to chemotherapy in cancer patients. In this Ph2 project, we aim to optimise manufacturing, validate through a clinical trial and bring to market SIMECOS: A nutraceutical for cancer patients derived from chitin purified T-ChOS™ molecules. SIMECOS targets lung, breast and pancreatic cancer patients, with survival rates after 5-year of 20%, 82.2% and 5.2%, respectively. SIMECOS is expected to increase their quality of life, thanks to its proven effects to decrease pain and fatigue. The high trends (30%-95%) among cancer patients to use complementary supplements entail a great business opportunity for SIMECOS as in Europe, there are more than 780,000 patients per year diagnosed with breast, pancreatic and lung cancer looking for solutions to decrease chemotherapy side effects and improve the effectiveness of their treatment. Clinically validated SIMECOS will help these patients. We expect SIMECOS to reach the market in 2020. By 2024, after our European expansion, SIMECOS will give a profit of €10.45M and considering a Phase 2 budget of €2.18M, the return-on-investment (ROI) will be 9.9


List of deliverables.
SIMECOS web page Websites, patent fillings, videos etc. 2020-03-19 15:44:56

Take a look to the deliverables list in detail:  detailed list of Simecos deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIMECOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIMECOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More